HilleVax

#9233

Rank

$104.76M

Marketcap

United States

Country

Leadership team

Dr. Robert M. Hershberg M.D., Ph.D. (Pres, CEO & Chairman)

Mr. David A. Socks (CFO & Chief Bus. Officer)

Mr. Aditya Kohli Ph.D. (COO & Director)

Products/ Services

Biopharma, Biotechnology, Pharmaceutical

Headquarters

Boston, Massachusetts, United States

Established

2021

Company Registration

SEC CIK number: 0001888012

Traded as

HLVX

Social Media

URL

https://www.hillevax.com

Overview

Location

Recognition and Award

References

Summary

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

History

HilleVax was founded in 1971 as a joint venture between US and German companies to produce innovative vaccines.

Mission

HilleVax’s mission is to research, develop, and deliver effective and safe vaccines to help improve the health of individuals and communities around the world.

Vision

HilleVax’s vision is to be the leading provider of vaccines, with a focus on creating innovative, safe, and effective products that help individuals achieve optimal health.

Key Team

Mr. Paul S. Bavier J.D. (Gen. Counsel, Sec. & Chief Admin. Officer)

Ms. Astrid Borkowski M.D., Ph.D. (Chief Medical Officer)

Dr. Anju Chatterji Ph.D. (Sr. VP of Technical Operations)

Ms. Kaia Agarwal (Sr. VP of Regulatory Affairs)

Recognition and Awards

HilleVax has been awarded numerous awards including the National Institutes of Health Award for Innovative Vaccines, the World Health Initiative Award for Outstanding Vaccine Development, and the European Union Award for Excellence in Vaccine Nonprofit Partnership.